NIH Trial Evaluating Remdesivir Plus Baricitinib for COVID-19 Initiated
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
The AAP has issued a statement regarding recent data published by the Centers for Disease Control and Prevention (CDC) about a decline in pediatric vaccination during the COVID-19 pandemic.
The FDA has launched a new webpage with information for recovered individuals who were infected with coronavirus disease 2019 (COVID-19) on where they can go to donate plasma to aid in the treatment of severely ill patients.
The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.
Although not approved by the Food and Drug Administration (FDA) for COVID-19, hydroxychloroquine and azithromycin have been gaining momentum as potential treatments based on results of small studies.
Convalescent plasma, which is collected from patients who have recovered from COVID-19, contains antibodies to SARS-CoV-2, the virus that causes the disease.
To expedite development, the FDA has created a special emergency program called the Coronavirus Treatment Acceleration Program.
The American College of Allergy, Asthma and Immunology (ACAAI) has issued a statement regarding the use of corticosteroids for patients with allergies and asthma.
The product that sickened the couple was in powder form and was labeled “for Ornamental Fish Use Only.”
The FDA has issued an Emergency Use Authorization for the Abbott ID Now™ COVID-19 test.